Today, four new shares of Huayan Jingji (301138), DEA shares (301177), Mengtian home (603216) and Baiji Shenzhou (688235) were listed.
Huayan precision machine is a high-tech enterprise mainly engaged in the design, R & D, production and sales of bottle blank intelligent forming system and bottle blank mould. At the same time, it can provide a series of customized bottle blank forming solutions such as mould renovation and maintenance, equipment upgrading and transformation, bottle blank bottle sample design and production line planning, so as to build an intelligent factory for downstream bottle blank manufacturers.
As of the signing date of the prospectus, Bao Helin and Wen Shixu directly held 38.1036% and 38.1036% of the company’s equity respectively, and indirectly held 9.5259% and 9.5259% of the company’s equity respectively through Baolai investment and Xuyang investment. Bao Helin and Wen Shixu jointly held 95.2590% of the company’s equity. On May 27, 2020, Bao Helin and Wen Shixu signed the agreement on concerted action. Bao Helin and Wen Shixu are the common controlling shareholders and actual controllers of the company.
The sponsor of the listing of Huayan Jingji is Caitong Securities Co.Ltd(601108) . The company raised 785 million yuan, which will be used to expand the production of bottle blank intelligent forming system, high-speed multi cavity mold, R & D center and supplement working capital.
DEA Co., Ltd. is mainly engaged in brand operation, customized sales, R & D and design of jewelry, and customized high-quality diamond inlaid jewelry such as proposal diamond rings for marriage and love people. The company mainly adopts the business model of self-supporting and customized sales, and is committed to brand construction, channel expansion, product R & D and supply chain integration of DR and other private brands.
As of the signing date of the prospectus, DEA investment holds 95% of the shares of the company. The actual controllers of the company are Zhang Guotao and Lu Yiwen. Zhang Guotao and Lu Yiwen are husband and wife. Zhang Guotao indirectly holds 7.975% of the shares of the company through DEA investment, Wendy No. 1, Wendy No. 2, Wendy No. 3 and Qianhai Wendy; Lu Yiwen indirectly holds 90.25% of the shares of the company through DEA investment. Zhang Guotao and Lu Yiwen indirectly hold 98.225% of the shares of the company and are the actual controllers of the company.
The sponsor of DEA’s listing is China Securities Co.Ltd(601066) . The company raised 4.676 billion yuan, which will be used for channel network construction projects, information system construction projects, diamond jewelry R & D creative design center construction projects and supplementary working capital projects.
Mengtian home is mainly engaged in the design, R & D, production and sales of customized furniture such as wooden doors, cabinets and wallboards, so as to provide consumers with overall space solutions for home.
The controlling shareholder of the company is Mengtian holding, holding 75% of the shares before the issuance. The actual controllers of the company are Yu Jingyuan and fan Xiaozhen. Yu Jingyuan controls 75% of the voting rights of the company through Mengtian holdings, and fan Xiaozhen directly holds 8% of the shares of the company. At the same time, Yu Jingyuan and fan Xiaozhen control 10% and 5% of the voting rights of the company through Mengjia investment and MengYue investment respectively. Therefore, Yu Jingyuan and fan Xiaozhen directly and indirectly own 98% of the voting rights of the company.
Mengtian home’s sponsor for this listing is Minsheng Securities Co., Ltd. The company raised 933 million yuan, which will be used for the annual output of 370000 flat doors, 90000 personalized customized cabinets, intelligent storage center construction project, brand channel construction project, information construction project and supplementary working capital.
Baiji Shenzhou is a global and commercial biotechnology company focusing on research, development, production and commercialization of innovative drugs.
As of September 30, 2020, the shareholding ratio of Amgen, the largest shareholder of the company, was 20.36%. During the reporting period, the company’s equity was relatively scattered, the equity or voting rights held by any single shareholder of the company did not exceed 30%, and there was no concerted action relationship between the major shareholders who directly held more than 5% of the company’s shares. Therefore, any single shareholder of the company could not control the general meeting of shareholders and was not enough to have a decisive impact on the resolutions of the general meeting of shareholders. There are 11 directors on the board of directors of the company. Due to the relatively scattered equity of the company, the number of directors nominated by any single shareholder of the company is less than half of the total number of members of the board of directors, which cannot control the board of directors of the issuer. To sum up, as of the signing date of this prospectus, the company has neither controlling shareholder nor actual controller.
The sponsor of Baiji Shenzhou’s listing is Goldman Sachs Gaohua Securities Co., Ltd., China International Capital Corporation Limited(601995) . The company raised 22.16 billion yuan, which will be used for drug clinical trial R & D projects, R & D center construction projects, production base R & D and industrialization projects, marketing network construction projects and supplementary working capital.
(China Economic Net)
